Drug intelligence / Profile preview

AFA-280

Development stage: Preclinical
Lead developer: AfaSci
Modality: Small Molecules

Overview

AFA-280 is a small molecule drug developed by AfaSci, Inc. It is in preclinical development for the treatment of inflammatory pain and neuroinflammation, with potential applications in other nervous system diseases. The mechanism of action involves inhibition of soluble epoxide hydrolase (sEH), which is associated with anti-inflammatory effects and modulation of neuroinflammatory pathways. By targeting sEH, AFA-280 aims to reduce inflammation and restore normal nervous system function without the use of opioids or NSAIDs[1][9]. IND-enabling studies are ongoing as of 2025.

Targets

EPHX2 (Soluble epoxide hydrolase)

Beyond the preview

Go deeper on AFA-280.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFA-280.

Explore the full profile